---
id: smallpox_065
category: organisms
tags: [smallpox, variola-virus, bioterrorism, tecovirimat, TPOXX, orthopoxvirus]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Smallpox (Variola Virus) - Bioterrorism Agent

**Q:** What are the clinical features of smallpox, how is it distinguished from other rashes, and what is the current treatment approach?

**A:**

**Microbiology:**
- **Variola virus** (double-stranded DNA virus)
- **Orthopoxvirus family** (related: vaccinia, mpox, cowpox)
- Human-specific pathogen

**Epidemiology:**
- **Eradicated in 1980** (last naturally occurring case: 1977 in Somalia)
- Exists only in 2 WHO-approved laboratories (US CDC, Russia)
- **CDC Category A bioterrorism agent** (highest threat level)
- No natural cases for >40 years → population susceptibility

---

**Clinical Presentation:**

**Transmission:**
- **Airborne droplets** (respiratory secretions)
- Direct contact with lesions or contaminated fomites
- **Highly contagious** (basic R₀ = 5-7)
- Infectious from onset of rash until all scabs fall off

**Incubation:** 7-19 days (average 10-14 days)

**Clinical Course:**

**1. Prodrome (2-4 days):**
- **High fever** (38-40°C)
- **Severe malaise, prostration**
- **Headache, backache** (lumbar pain characteristic)
- **Vomiting** (in 50%)
- **NO rash yet**

**2. Enanthem (Day 0-1 of Rash):**
- **Oral lesions** (small red spots on tongue, mouth) appear first
- Break down → ulcers
- **Patient becomes highly infectious** (virus in oropharynx)

**3. Exanthem (Rash):**

**Day 0-1:**
- **Maculopapular rash** begins on **face, forearms, hands**
- Spreads **centrifugally** (face/extremities → trunk)

**Day 2-3:**
- Papules → **vesicles** (fluid-filled)

**Day 4-5:**
- Vesicles → **pustules** (deep, firm, umbilicated)
- **All lesions in same stage** (synchronous evolution)

**Day 7-14:**
- Pustules → **scabs/crusts**
- Scabs fall off over 1-2 weeks
- **Pitted scars** (pockmarks) remain

**Key Features:**
- **Centrifugal distribution** (face > extremities > trunk)
- **Palms and soles involved** (90%)
- **All lesions in same stage** (synchronous)
- **Deep, firm pustules** (feel like BB pellets embedded in skin)

---

**Types of Smallpox:**

**1. Ordinary Smallpox (90% of cases):**
- Classic presentation (above)
- Mortality: 30%

**2. Modified Smallpox (Vaccinated Patients):**
- Milder disease
- Fewer lesions, evolve faster
- Lower mortality (1-10%)

**3. Flat Smallpox (Malignant Smallpox - 5%):**
- Lesions remain **flat, soft** (never pustulate)
- Severe toxicity
- Mortality: 95%

**4. Hemorrhagic Smallpox (5%):**
- **Early type:** Hemorrhage before rash
- **Late type:** Hemorrhage into pustules
- Mortality: ~100%

---

**Differential Diagnosis (Key Distinguishing Features):**

**Smallpox vs Chickenpox (Varicella):**

| **Feature** | **Smallpox** | **Chickenpox** |
|-------------|--------------|----------------|
| **Prodrome** | **Severe** (high fever, prostration) | Mild or absent |
| **Distribution** | **Centrifugal** (face > extremities) | **Centripetal** (trunk > extremities) |
| **Palms/soles** | ✅ **Involved** (90%) | ❌ Rare |
| **Lesion evolution** | **Synchronous** (all same stage) | **Asynchronous** (multiple stages) |
| **Lesion depth** | **Deep, firm** (embedded) | Superficial, soft |
| **Fever** | Before rash, then ↓ | Concurrent with rash |
| **Umbilication** | Deep, firm | Shallow |

**Mnemonic: "Smallpox = Same Stage, Starts face/limbs, Severe prodrome"**

**Smallpox vs Mpox (Monkeypox):**

| **Feature** | **Smallpox** | **Mpox** |
|-------------|--------------|----------|
| **Lymphadenopathy** | ❌ Absent | ✅ **Prominent** (75%) |
| **Distribution** | Centrifugal | Variable (recent outbreak: anogenital) |
| **Mortality** | 30% | 1-10% (clade II), up to 10% (clade I) |
| **Person-to-person** | ✅ Highly contagious | Less contagious |

---

**Diagnosis:**

**Clinical Suspicion (Bioterrorism Alert):**
- **ANY case of suspected smallpox = public health emergency**
- Notify CDC immediately

**Laboratory Diagnosis:**
- **PCR** (variola-specific)
- **Electron microscopy** (orthopoxvirus, cannot distinguish species)
- **Viral culture** (BSL-4 only, CDC/WHO reference labs)

**Specimens:**
- Vesicle/pustule fluid (unroof lesion)
- Scab material
- Oropharyngeal swab

**Do NOT Send to Local Lab:**
- Alert CDC/state health department first
- Specimens handled only in designated labs

---

**Treatment:**

**1. Tecovirimat (TPOXX) - FDA-Approved 2018:**

**Mechanism:**
- Inhibits **VP37 protein** (viral egress)
- Prevents virus release from infected cells

**Dosing:**

| **Weight** | **Dosing** | **Duration** |
|------------|------------|--------------|
| **≥13 kg - <25 kg** | 200 mg PO BID | 14 days |
| **≥25 kg - <40 kg** | 400 mg PO BID | 14 days |
| **≥40 kg - <120 kg** | 600 mg PO BID | 14 days |
| **≥120 kg** | 600 mg PO TID | 14 days |

**Notes:**
- **Take with fatty meal** (↑ absorption)
- Available from **Strategic National Stockpile (SNS)**
- Administered under **Expanded Access IND** (compassionate use)

**Efficacy:**
- FDA-approved under **Animal Rule** (cannot test in humans)
- 100% survival in nonhuman primates infected with variola (vs 50% placebo)
- Effective when started 2-4 days post-infection

**2. Brincidofovir (CMX001):**
- Alternative antiviral (not FDA-approved for smallpox yet)
- Available from SNS
- Reserved for tecovirimat-resistant cases

**3. Cidofovir:**
- IV antiviral (nephrotoxic)
- Less preferred (toxicity, IV route)

**4. Vaccinia Immune Globulin (VIGIV):**
- For severe vaccine complications (eczema vaccinatum, progressive vaccinia)
- NOT proven effective for smallpox treatment

**5. Supportive Care:**
- Fluid/electrolyte management
- Pain control
- Secondary bacterial infection treatment (if needed)

---

**Post-Exposure Prophylaxis:**

**Vaccination (Smallpox Vaccine):**

**Indications:**
- Exposure to confirmed/suspected smallpox case
- Laboratory workers handling variola
- Military/first responders (pre-event vaccination)

**Vaccines Available:**

| **Vaccine** | **Type** | **Efficacy** |
|-------------|----------|--------------|
| **ACAM2000** | Live vaccinia virus (replication-competent) | High |
| **JYNNEOS (Imvamune)** | Live vaccinia virus (replication-deficient) | High |

**Post-Exposure Timing:**
- **Within 3 days:** 95% protection
- **Within 4-7 days:** Some protection, milder disease

**Vaccine Complications:**
- Eczema vaccinatum (disseminated vaccinia in eczema patients)
- Progressive vaccinia (immunocompromised)
- Myopericarditis (ACAM2000)

**Tecovirimat for PEP:**
- Consider if vaccination contraindicated (immunosuppressed, eczema)
- Begin within 14 days of exposure

---

**Infection Control:**

**Isolation:**
- **Airborne + contact precautions**
- Negative pressure room
- N95 masks (or higher)
- Isolation until **all scabs fall off**

**Quarantine:**
- Close contacts → quarantine x 17 days (monitor for fever)

**Vaccination of Contacts:**
- "Ring vaccination" strategy (vaccinate close contacts)

---

**Bioterrorism Scenario:**

**Aerosolized Variola Virus:**
- **Incubation 10-14 days** → delayed recognition
- Initial cases misdiagnosed as chickenpox
- **High contagiousness** → rapid spread
- Population susceptibility (last mass vaccination ended 1972 in US)

**Response:**
- Case isolation (airborne/contact precautions)
- Contact tracing + ring vaccination
- Mass vaccination (if widespread outbreak)
- Tecovirimat treatment (SNS)
- Quarantine exposed contacts

---

**Mnemonic: "SMALLPOX = Same Stage, Malaise first, All body (centrifugal), Lesions deep, Palms/soles, Only human, eXterminated"**
- **S**ame stage (synchronous evolution)
- **M**alaise/prostration (severe prodrome)
- **A**ll body (centrifugal: face/limbs first)
- **L**esions deep, firm ("BB pellets")
- **P**alms and soles (90%)
- **O**nly human pathogen
- **X**terminated (eradicated 1980)

**Mnemonic: "Chickenpox vs Smallpox: Crop vs Same"**
- Chickenpox = **Crop** of lesions (different stages)
- Smallpox = **Same** stage (synchronous)

**Clinical Pearls:**
- **ANY suspected smallpox case = bioterrorism** (no natural cases since 1977)
- **Centrifugal distribution** (face/extremities > trunk) distinguishes from chickenpox (centripetal)
- **All lesions in same stage** = key feature (vs chickenpox = multiple stages)
- **Palms and soles involved** (90%) - very suggestive
- **Deep, firm pustules** feel like BB pellets embedded in skin
- **Tecovirimat (TPOXX) FDA-approved** for smallpox treatment (available from SNS)
- **Vaccination within 3 days of exposure** → 95% protection
- **Notify CDC immediately** if suspected case (do NOT send specimens to local lab)
- Population susceptibility high (routine vaccination ended 1972 in US, 1980 globally)
- **Airborne + contact precautions** (unlike mpox, which is primarily contact)
- Highly contagious (R₀ = 5-7) → rapid epidemic potential

**Media:** None

**Sources:** [CDC 2024 - Smallpox clinical treatment], [FDA 2018 - Tecovirimat approval], [NEJM Evidence 2024 - Tecovirimat for mpox], [PMC 2022 - Overview tecovirimat], [PMC 2013 - Efficacy in nonhuman primates], [PubMed 2019 - Development and approval tecovirimat], [Medscape 2024 - TPOXX dosing]
